X4 Pharmaceuticals Inc has a consensus price target of $4, established from looking at the 16 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., B. Riley Securities, and HC Wainwright & Co. on March 22, 2024, December 12, 2023, and August 11, 2023. With an average price target of $2.33 between HC Wainwright & Co., B. Riley Securities, and HC Wainwright & Co., there's an implied 74.13% upside for X4 Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/22/2024 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 123.88% | HC Wainwright & Co. | Swayampakula Ramakanth | → $3 | Reiterates | Buy → Buy | Get Alert |
12/12/2023 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | -25.37% | B. Riley Securities | Kalpit Patel | $3 → $1 | Downgrade | Buy → Neutral | Get Alert |
08/11/2023 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 123.88% | HC Wainwright & Co. | Swayampakula Ramakanth | → $3 | Reiterates | Buy → Buy | Get Alert |
05/17/2023 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 273.13% | Stifel | Stephen Willey | $4 → $5 | Maintains | Buy | Get Alert |
05/05/2023 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 123.88% | HC Wainwright & Co. | Swayampakula Ramakanth | → $3 | Reiterates | → Buy | Get Alert |
04/10/2023 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 123.88% | B. Riley Securities | Mayank Mamtani | $7 → $3 | Maintains | Buy | Get Alert |
03/24/2023 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 198.51% | Oppenheimer | Leland Gershell | $5 → $4 | Maintains | Outperform | Get Alert |
03/22/2023 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 123.88% | Cantor Fitzgerald | Kristen Kluska | → $3 | Maintains | Overweight | Get Alert |
03/22/2023 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 123.88% | HC Wainwright & Co. | Swayampakula Ramakanth | $5 → $3 | Maintains | Buy | Get Alert |
12/22/2022 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 123.88% | Cantor Fitzgerald | Kristen Kluska | → $3 | Initiates | → Overweight | Get Alert |
12/12/2022 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 123.88% | Piper Sandler | Edward Tenthoff | → $3 | Initiates | → Overweight | Get Alert |
11/30/2022 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 273.13% | HC Wainwright & Co. | Swayampakula Ramakanth | $3.5 → $5 | Maintains | Buy | Get Alert |
05/19/2022 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 422.39% | B. Riley Securities | Mayank Mamtani | $10 → $7 | Maintains | Buy | Get Alert |
05/13/2022 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 534.33% | HC Wainwright & Co. | Swayampakula Ramakanth | $11 → $8.5 | Maintains | Buy | Get Alert |
04/05/2022 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 646.27% | Canaccord Genuity | Arlinda Lee | $20 → $10 | Maintains | Buy | Get Alert |
12/14/2021 | XFOR | Buy Now | X4 Pharmaceuticals | $1.34 | 720.9% | HC Wainwright & Co. | Swayampakula Ramakanth | — | Maintains | Buy | Get Alert |
The latest price target for X4 Pharmaceuticals (NASDAQ: XFOR) was reported by HC Wainwright & Co. on March 22, 2024. The analyst firm set a price target for $3.00 expecting XFOR to rise to within 12 months (a possible 123.88% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for X4 Pharmaceuticals (NASDAQ: XFOR) was provided by HC Wainwright & Co., and X4 Pharmaceuticals reiterated their buy rating.
There is no last upgrade for X4 Pharmaceuticals.
The last downgrade for X4 Pharmaceuticals Inc happened on December 12, 2023 when B. Riley Securities changed their price target from $3 to $1 for X4 Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of X4 Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for X4 Pharmaceuticals was filed on March 22, 2024 so you should expect the next rating to be made available sometime around March 22, 2025.
While ratings are subjective and will change, the latest X4 Pharmaceuticals (XFOR) rating was a reiterated with a price target of $0.00 to $3.00. The current price X4 Pharmaceuticals (XFOR) is trading at is $1.34, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.